The history of ifosfamide

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ifosfamide was developed by investigators at AstaWerke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chlorethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less myelosuppression, but more commonly produced hemorrhagic cystitis as its dose-limiting toxicity. This toxicity has been minimized with the urothelial protective agents mesna and N-acetylcysteine. Thus, increasing doses have been administered and a new spectrum of toxicities observed, including neurotoxicity, hematologic toxicity, nephrotoxicity, and acidosis. Ifosfamide has been shown to have a broad spectrum of clinical activity in various cancers. Questions remain as to the optimal doses and schedules.

Original languageEnglish
Pages (from-to)2-6
Number of pages5
JournalSeminars in Oncology
Volume19
Issue number6 SUPPL. 12
StatePublished - 1992

Fingerprint

Ifosfamide
History
Cyclophosphamide
Mesna
Protective Agents
Cystitis
Acetylcysteine
Acidosis
Germany
Appointments and Schedules
Nitrogen
Research Personnel
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

The history of ifosfamide. / Loehrer, Patrick.

In: Seminars in Oncology, Vol. 19, No. 6 SUPPL. 12, 1992, p. 2-6.

Research output: Contribution to journalArticle

Loehrer, P 1992, 'The history of ifosfamide', Seminars in Oncology, vol. 19, no. 6 SUPPL. 12, pp. 2-6.
Loehrer, Patrick. / The history of ifosfamide. In: Seminars in Oncology. 1992 ; Vol. 19, No. 6 SUPPL. 12. pp. 2-6.
@article{1881fda384ef43278e596ad8bef7f757,
title = "The history of ifosfamide",
abstract = "Ifosfamide was developed by investigators at AstaWerke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chlorethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less myelosuppression, but more commonly produced hemorrhagic cystitis as its dose-limiting toxicity. This toxicity has been minimized with the urothelial protective agents mesna and N-acetylcysteine. Thus, increasing doses have been administered and a new spectrum of toxicities observed, including neurotoxicity, hematologic toxicity, nephrotoxicity, and acidosis. Ifosfamide has been shown to have a broad spectrum of clinical activity in various cancers. Questions remain as to the optimal doses and schedules.",
author = "Patrick Loehrer",
year = "1992",
language = "English",
volume = "19",
pages = "2--6",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 12",

}

TY - JOUR

T1 - The history of ifosfamide

AU - Loehrer, Patrick

PY - 1992

Y1 - 1992

N2 - Ifosfamide was developed by investigators at AstaWerke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chlorethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less myelosuppression, but more commonly produced hemorrhagic cystitis as its dose-limiting toxicity. This toxicity has been minimized with the urothelial protective agents mesna and N-acetylcysteine. Thus, increasing doses have been administered and a new spectrum of toxicities observed, including neurotoxicity, hematologic toxicity, nephrotoxicity, and acidosis. Ifosfamide has been shown to have a broad spectrum of clinical activity in various cancers. Questions remain as to the optimal doses and schedules.

AB - Ifosfamide was developed by investigators at AstaWerke in Germany. Its chemical structure differs from that of cyclophosphamide by the transposition of one of the side chain chlorethyl groups to the ring nitrogen. In several preclinical models, ifosfamide had greater activity than cyclophosphamide. It produced less myelosuppression, but more commonly produced hemorrhagic cystitis as its dose-limiting toxicity. This toxicity has been minimized with the urothelial protective agents mesna and N-acetylcysteine. Thus, increasing doses have been administered and a new spectrum of toxicities observed, including neurotoxicity, hematologic toxicity, nephrotoxicity, and acidosis. Ifosfamide has been shown to have a broad spectrum of clinical activity in various cancers. Questions remain as to the optimal doses and schedules.

UR - http://www.scopus.com/inward/record.url?scp=0027076598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027076598&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 2

EP - 6

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 12

ER -